This study examined the clinical characteristics of patients with refractory chronic cough or unexplained chronic cough enrolled in a multicenter, randomized, Phase IIb trial of gefapixant versus placebo. Cough-related characteristics were measured at baseline, and included objective awake cough frequency and patient-reported outcomes. 24-Hour objective cough frequency was measured using the Vitalograph VitaloJAK acoustic recording device.
- Author Morice AH et al.
- Publication Lung
- Year 2021
- Device Type VitaloJAK
